

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy

SUMMARY

Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approved label for pretomanid restricts its use to the regimen comprising bedaquiline, pretomanid and linezolid (BPaL) and only for extensively drug-resistant-TB or multidrug-resistant TB, “when antibiotics used for the latter form of TB do not work or cause unacceptable side effects.” This restricted use implies that the older,

prolonged and poorly tolerated regimens remain the recommended treatment for most cases of drug-resistant TB. The authors, representing many respiratory groups and societies, call for the label expansion of pretomanid to align with global guidelines, allowing for broader use.

KEY WORDS: tuberculosis; drug resistance; MDR-TB; RR-TB; XDR-TB; European Medicines Agency

We express our strong support for the proposed label expansion of pretomanid, a key anti-TB drug, which is included on the WHO model list of essential medicines.¹ This initiative aims to align clinical practice with the latest WHO guidelines² and updated guidelines by the American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America.³ The current EMA-approved label for pretomanid (Dovprela®) tablets restricts its use to the regimen comprising bedaquiline, pretomanid and linezolid (BPaL) and only for extensively drug-resistant-TB (XDR-TB) or for multidrug-resistant (MDR-TB) “when antibiotics used for this form of tuberculosis do not work or cause unacceptable side effects”.⁴ In this context, it is important to highlight that the definition of XDR-TB was revised by WHO in 2021, after pretomanid (Dovprela®) authorisation, and now describes a different patient population,⁵ those with *Mycobacterium tuberculosis* resistance against rifampicin (with or without isoniazid), levofloxacin or moxifloxacin, and bedaquiline and/or linezolid.

This restricted use implies that the older, prolonged and poorly tolerated individualised regimens remain the recommended treatment for most persons affected by MDR-TB or rifampicin-resistant TB (RR-TB). However, since 2022, and based on evidence from the NiX, ZeNix and TB-PRACTECAL trials, WHO has recommended BPaL with moxifloxacin (BPaLM) as the standard of care for MDR/RR-TB. Furthermore, WHO advises omitting moxifloxacin in cases of fluoroquinolone resistance.^{6–8} Following the WHO 2022 guidelines recommending programmatic use of BPaL(M) for all patients with rifampicin-resistant TB, WHO issued a Call to Action⁹ emphasising that rapid implementation of these regimens could significantly improve treatment outcomes and patient

quality of life. WHO urged governments, healthcare providers and stakeholders to prioritise the integration of BPaL(M) into national TB programs.

The BPaL(M) regimen has been implemented in individual countries through pilot programs, clinical trials, operational research and programmatic settings. Notably, the mBPaL trial in India,¹⁰ a prospective cohort study in Belarus and Uzbekistan,¹¹ and a pilot implementation study in Pakistan,¹² demonstrated high success rates and a safety profile consistent with the results of the earlier Nix-TB, ZeNix and TB-PRACTECAL trials. Furthermore, the BPaL(M) regimen has been shown to be cost-effective across four countries.^{13,14} Shortening the duration of treatment is a priority for MDR/RR-TB patients, along with reducing pill burden and tolerability of new regimens.¹⁵ However, recent data from TBNet and WHO-EURO surveys assessing the availability of drugs and resistance testing in Europe highlight significant disparities in access to the BPaL(M) regimen. These findings reveal that of the surveyed countries, only 23/44 (52%) and 3/18 (17%), respectively, have full access to all necessary drugs, with pretomanid being notably the least accessible.^{7,16}

In EU/EEA countries, numbers of MDR/RR-TB cases are increasing. Therefore, we urge an expedited review of the pretomanid (Dovprela®) label by the EMA. A recent review supports the use of pretomanid-based regimens in patients with drug-resistant TB and found that pretomanid-based regimens are efficacious with tolerable safety profile.¹⁷ An updated label that includes broader indications for pretomanid will not only align with the best clinical practices and WHO recommendations but also address the urgent need for equitable access to treatment across Europe.

We strongly advocate for a label update that reflects the WHO’s current guidelines on use of pretomanid to improve treatment accessibility and efficacy.

L. KUKSA,¹ C. ANDREJAK,² B. HAECKER,³ G. BOTHAMLEY,^{4,5} A. CALCAGNO,⁶ D.M. CIRILLO,⁷ R. DUARTE,^{8,9,10} R. FATIMA,¹¹ G. FERLAZZO,¹² L. GUGLIEMMETTI,^{13,14} G. GÜNTHER,¹⁵ C. HEWISON,¹⁶ C.R. HORSBURGH,¹⁷ T. JÄGER,¹⁸ Y. KALANCHA,¹⁹ R. OTTO-KNAPP,³ K. KRANZER,^{20,21,22,23} T. LILLEBAEK,^{24,25} G. MARKS,^{26,27} K. MIDDELKOOP,^{28,29} I. MOTTA,^{12,30} V. RABINOVA,¹⁹ P. SOMMERFELD,³¹ P. TATTEVIN,³² C. LANGE^{33,34,35,36}

¹Riga East University Hospital, Tuberculosis and Lung Disease center, Riga, Latvia; ²Pneumology Department, University Hospital Centre Amiens-Picardie, Amiens, France; ³German Central Committee against Tuberculosis (DZK), Berlin, Germany; ⁴Homerton University Hospital, London, UK; ⁵London School of Hygiene & Tropical Medicine, London, UK; ⁶Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy; ⁷IRCCS San Raffaele Scientific Institute, Milan, Italy; ⁸EPIUnit ITR, Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal; ⁹Estudos das Populações, ICBAS - Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal; ¹⁰INSA – Instituto de Saúde Pública Doutor Ricardo Jorge, INSA Porto, Porto, Portugal; ¹¹United Nations Office for Project Services (UNOPS), Islamabad, Pakistan; ¹²Médecins Sans Frontières Access Campaign, Geneva, Switzerland; ¹³Sorbonne Université, Institut national de la santé et de la recherche médicale, Unité 1135, Centre d'Immunologie et des Maladies Infectieuses, Paris France; ¹⁴Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries, Paris, France; ¹⁵Department of Pulmonology, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; ¹⁶Médecins Sans Frontières, Tuberculosis, Working Group, Paris, France; ¹⁷Boston University School of Public Health, Department of Global Health, Boston, MA, USA; ¹⁸German Center for Infection Research (DZIF), Braunschweig, Germany; ¹⁹TB Europe Coalition, Kyiv, Ukraine; ²⁰Clinical Research Department, London School of Hygiene & Tropical Medicine, UK; ²¹The Health Research Unit Zimbabwe, Biomedical Research and Training Institute, Zimbabwe; ²²Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany; ²³German Center for Infection Research (DZIF), partner site Munich, Germany; ²⁴International Reference Laboratory of Mycobacteriology, Statens Serum Institut, Copenhagen, Denmark; ²⁵Global Health Section, Department of Public Health, University of Copenhagen, Copenhagen, Denmark; ²⁶The Woolcock Institute, of Medical Research, Macquarie Park, NSW, Australia; ²⁷Division of Global Health, Burnet Institute, Melbourne, VIC, Australia;

²⁸Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town; ²⁹Desmond Tutu HIV Centre, Department of Medicine, University of Cape Town, Cape Town; ³⁰MRC Clinical Trials Unit, University College London, London, UK; ³¹TB Alert, London, UK; ³²Infectious Diseases & Intensive Care Unit, Pontchaillou University Hospital, Rennes, France; ³³Department of Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center, Borstel, Germany; ³⁴German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Germany; ³⁵Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany; ³⁶Baylor College of Medicine and Texas Children's Hospital, Global Tuberculosis Program, Houston, TX, USA.

Correspondence to: Christoph Lange, Clinical Infectious Diseases, Parkallee 35, 23845 Borstel, Germany. E-mail: clange@fz-borstel.de

Acknowledgements

The authors represent the following groups: Study Group on Mycobacterial Infections of the European Society for Clinical Microbiology and Infectious Diseases (ESGMYC), the European Reference Laboratory Network for TB (ERLN-TB-Net-3), the European Society of Mycobacteriology (ESM), the French Society of Infectious Diseases (FSID), the French Society of Respiratory Diseases (SPLF), the German Center for Infection Research (DZIF), the German Central Committee for the Fight against Tuberculosis (DZK), the International Union against Tuberculosis and Lung Diseases (the UNION), the Italian Society of Infectious Diseases (SIMIT), Médecins Sans Frontières (MSF), TB Alert, TB Europe Coalition and the Tuberculosis Network European Trialsgroup (TBnet).

Conflicts of interest: GB is a member of the UK MDR-TB Clinical Advisory Group. CC reports research grants from Gilead, Viiv, MSD and honoraria for speaking at sponsored symposia and for consultations from Gilead, Viiv, MSD and Johnson&Johnson. GF is a TB medical adviser for MSF International and had a consultancy contract with the Global Fund during the period 2022-2023 as TB Preventive treatment consultant. LG reports funding from UN-TAID for the endTB project where he serves as PI of two clinical trials. He reports pro-bono donation of pretomanid from Viartis for the independent, investigator-initiated FAST-MDR trial where he serves as PI. GM is the President and former acting Executive Director of The International Union against Tuberculosis and Lung Diseases (The Union). IM reports a role as a medical monitor for the TB-PRACTECAL trial (MSF UK/Italy) from 2017– 2023. ROK reports receiving an honorarium for lectures and a workshop sponsored by MSD. CL reports receiving a honorarium for lectures sponsored by Astra Zeneca, Gilead, GSK, Inmed, medupdate and medUpdate Europe, is the Secretary General of the Union, and is supported by the German Center for Infection Research (DZIF) under grant agreement TTU-TB 02.702.

References

- 1 World Health Organization. WHO model lists of essential medicines. Geneva, Switzerland: WHO, 2025.
- 2 World Health Organization. Key updates to the treatment of drug-resistant tuberculosis: rapid communication. Geneva, Switzerland: WHO, 2024.
- 3 Saukkonen JJ, et al. Updates on the treatment of drug-susceptible and drug-resistant tuberculosis. An official ATS/CDC/

- ERS/IDSA Clinical Practice Guideline. *Am J Respir Crit Care Med* 2025;211(1):15–33.
- 4 European Medicines Agency. Dovprela (previously Pretomanid FGK). Amsterdam, The Netherlands: EMA, <https://www.ema.europa.eu/en/medicines/human/EPAR/dovprela>.
 - 5 Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27–29 October 2020. Geneva, Switzerland: WHO, 2021.
 - 6 World Health Organization. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. Geneva, Switzerland: WHO, 2022.
 - 7 Günther G, et al. Tuberculosis Network European Trials Group. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPAL(M)) regimen for rifampicin-resistant tuberculosis in Europe. *Clin Microbiol Infect* 2024;30(9):1197 e–e4.
 - 8 World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva, Switzerland: WHO, 2022.
 - 9 World Health Organization. Calls for action. Geneva, Switzerland: WHO, 2023. <https://www.who.int/campaigns/world-tb-day/2023/calls-to-action>.
 - 10 Padmapriyadarsini C, et al. Effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in treatment of drug-resistant pulmonary tuberculosis: open-label, randomized clinical trial. *Clin Infect Dis* 2024;79(6):1375–85.
 - 11 Sinha A, et al. The effectiveness and safety of bedaquiline, pretomanid, and linezolid (bpal)-based regimens for rifampicin-resistant tuberculosis in non-trial settings—a prospective cohort study in Belarus and Uzbekistan. *Clin Infect Dis* 2025;ciaf035.
 - 12 Khan MA, et al. Experience of piloting BPALM/BPAL for DR-TB care at selected sites in Pakistan. *IJTL Open* 2024;1(11):508–515.
 - 13 Auer C, et al. Savings from the introduction of BPAL and BPALM regimens at the country level. *IJTL Open* 2024;1(7):314–319.
 - 14 Evans D, et al. Cost and cost-effectiveness of BPAL regimen used in drug-resistant TB treatment in the Philippines. *IJTL Open* 2024;1(6):242–249.
 - 15 South A, et al. Patients' priorities around drug-resistant tuberculosis treatment: A multi-national qualitative study from Mongolia, South Africa and Georgia. *Glob Public Health* 2023;18(1):2234450.
 - 16 Otto-Knapp R, et al. Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023. *Euro Surveill* 2024;29(17):2400211.
 - 17 Thuy HT, et al. Efficacy and safety data on pretomanid for drug-resistant TB. *IJTL Open* 2025;2(2):73–82.

IJTL OPEN welcomes the submission of research articles on all aspects of TB and respiratory diseases such as asthma, bronchiectasis, COVID-19, COPD, child lung health and the hazards of tobacco and air pollution.

This is an open access article published by The Union under the terms of the Creative Commons Attribution License CC-BY.

For information on IJTL OPEN see: <https://theunion.org/our-work/journals/ijtl-open> or contact: journal@theunion.org



If you found this article interesting, you can explore related courses offered by The Union.

Learn more here: <https://theunion.org/our-work/union-courses>